Market Overview

AMD's Earnings Aren't Enough To Support Its Valuation, Analyst Says

AMD's Earnings Aren't Enough To Support Its Valuation, Analyst Says
Related AMD
The Chips Are Down: Weak Forecasts Hurt Semiconductor Stocks
Friday Follies: Brexit, Semiconductor, And Tariffs All Take Center Stage
Nvidia Plunges: Growth Is Gone (Seeking Alpha)

Advanced Micro Devices, Inc. (NASDAQ: AMD) reported fourth-quarter non-GAAP earnings of 8 cents per share compared to a 1-cent per share loss a year-ago. Revenues were up 33 percent year-over-year to $1.48 billion in the earnings report, issued after the close Tuesday. 

The results exceeded Street estimates.

The Analyst

Morgan Stanley analyst Joseph Moore reiterated an Underweight rating on AMD with an $8 price target.

The Thesis

The fourth-quarter results reflect solid execution, but even with tailwinds, it is hard for the earnings to justify the stock price, Moore said in a Wednesday note.

This is despite the analyst's view that ethereum's 300-percent move since October could drive strong mining revenues  and that AMD's core business possesses have growth potential.

Concerns include a deceleration in mining that would reduce units and ASPs in discreet graphics, making it hard for the strong product momentum in AMD's core business to offset the drop, Moore said. 

Revenues and earnings per share, though exceeding Street forecasts, trailed estimates in Q4. Revenue in the computing and graphics segment rose 17 percent sequentially to $958 million, thanks to crypto mining and Ryzen CPU demand, the analyst said. 

The enterprise, embedded and semi-custom segments saw a 37-percent sequential drop, hurt by a seasonal decline in consoles, Moore said. 

AMD's Q1 revenue guidance was above the consensus estimate and in-line with its recently raised numbers after adjusting for accounting, according to Morgan Stanley. 

The research firm lowered its calendar year 2018 EPS estimate by 4 cents to 31 cents; and by 2 cents to 31 cents in 2019 to reflect higher operating expenditures and taxes, Moore said. About $1.3 billion in incremental revenue from Zen in 2019 takes Morgan Stanley's calendar year 2018 revenue estimate to $6 billion, he said. 

"We see 2018 as a very strong year on multiple fronts," Moore said. " ... But we're not sure that in totality those things get better in 2019, which limits our willingness to pay a high multiple on 2018 earnings."

The Price Action

AMD shares are up over 20 percent over the past year.

The stock was last seen trading up 6.06 percent at $13.65 Wednesday afternoon. 

Related Links:

Samsung Enters The Cryptocurrency Mining Space, Announces First-Ever Stock Split

Expect Nvidia, AMD To Ride Cryptocurrency Wave Into 2018

Photo by Cosmic73/Wikimedia.

Latest Ratings for AMD

Oct 2018BairdMaintainsNeutralNeutral
Oct 2018BMO CapitalMaintainsMarket PerformMarket Perform
Oct 2018BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for AMD
View the Latest Analyst Ratings

Posted-In: crypto miningAnalyst Color Cryptocurrency Price Target Reiteration Top Stories Markets Analyst Ratings Best of Benzinga


Related Articles (AMD)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Cryptocurrency Ratings Agency Explains Bitcoin's C+ Grade

Earnings Preview For Vertex Pharmaceuticals